文献速递前列腺癌

PARP抑制剂作为转移性前列腺癌治疗新选择:系统综述

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-05-04

该系统综述检索PubMed和ClinicalTrials.gov,评估PARP抑制剂在转移性去势抵抗性前列腺癌(mCRPC)中的疗效。共纳入5篇论文和4篇摘要及16项临床试验。奥拉帕利单药或联合阿比特龙+泼尼松在DDR缺陷患者中显示rPFS和ORR获益;rucaparib在BRCA1/2突变患者中显示PSA应答率和ORR获益。

要点

  • 奥拉帕利单药或联合阿比特龙+泼尼松在DDR缺陷mCRPC中改善rPFS和ORR。
  • Rucaparib在BRCA1/2突变mCRPC中改善PSA应答率和ORR。
  • 尼拉帕利和他拉唑帕利等PARP抑制剂正在III期试验中评估。

核心结论

  • 奥拉帕利是首个在DDR缺陷前列腺癌中显示rPFS和ORR获益的PARP抑制剂,单药或联合阿比特龙+泼尼松均有效。
  • Rucaparib在BRCA1/2突变患者中显示PSA应答率和ORR获益。
  • 其他PARP抑制剂(尼拉帕利、他拉唑帕利)正在III期试验中评估,单药或联合AR信号抑制剂。

研究设计与样本

  • 系统综述,2020年1月检索PubMed Medline数据库,遵循PRISMA指南。
  • 检索词包括去势抵抗性前列腺癌、PARP抑制剂、DNA修复、同源重组修复等。
  • 同时检索ClinicalTrials.gov上奥拉帕利、尼拉帕利、他拉唑帕利、维利帕利和rucaparib在mCRPC中的 ongoing 临床试验。
  • 初检176篇文章,经标题和摘要筛选后纳入5篇论文和4篇摘要;另纳入16项临床试验。

主要发现

  • 奥拉帕利单药或联合阿比特龙+泼尼松在DDR缺陷前列腺癌中显示rPFS和ORR获益。
  • Rucaparib在II期研究中使BRCA2和BRCA1突变患者的PSA应答率和ORR获益。
  • 其他III期试验正在评估尼拉帕利和他拉唑帕利,单药或联合AR信号抑制剂。

临床怎么用

  • 对于DDR缺陷的mCRPC患者,可考虑使用奥拉帕利单药或联合阿比特龙+泼尼松治疗。
  • 对于BRCA1/2突变的mCRPC患者,rucaparib可作为治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A great number of DNA-damage repair (DDR) pathways have been recognized to be frequently dysregulated in advanced stages of prostate cancer. DNA-repair defects in prostate cancer represents a clinically relevant disease subset. Tumors whose ability to repair double-strand DNA breaks by homologous recombination is compromised, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase (PARP). METHODS: A systematic review of the literature has been conducted in January 2020 using PubMed Medline database in line with the recommendations from the PRISMA guidelines. The following string terms were used for searching clinical trial articles: castration resistant OR castrate resistance OR castration refractory AND prostate cancer AND PARP OR poly(ADP-ribose) polymerase inhibitor OR DNA-repair OR homologous recombination repair. On-going clinical trials with olaparib, niraparib, talazoparib, veliparib, and rucaparib in mCRPC were searched on the clinicalTrials.gov website. RESULTS: From this research 176 articles were identified. After title screening and abstract reading, five papers and four abstract were considered for the systematic review. Thirty-two clinical trials were also identified: from these 16 trials which did not include mCRPC patients or only prostate cancer patients, trials not yet recruiting and trials including radio-metabolic treatments were excluded. Sixteen trials were included and discussed in the paper. CONCLUSIONS: Olaparib has been the first agent showing a benefit in terms of rPFS and ORR alone or in combination with abiraterone plus prednisone in patients with DDR deficiency prostate cancer. Also rucaparib showed a benefit in terms of PSA response rate and ORR in patients with BRCA2 and BRCA1 mutation in a phase-II study. Other phase-III clinical trials are evaluating niraparib and talazoparib, alone or in combination with AR signaling inhibitors.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ratta R, Guida A, Scotté F, et al. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2020. PMID: 32367009. doi:10.1038/s41391-020-0233-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。